"Mannitol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A diuretic and renal diagnostic aid related to sorbitol. It has little significant energy value as it is largely eliminated from the body before any metabolism can take place. It can be used to treat oliguria associated with kidney failure or other manifestations of inadequate renal function and has been used for determination of glomerular filtration rate. Mannitol is also commonly used as a research tool in cell biological studies, usually to control osmolarity.
Descriptor ID |
D008353
|
MeSH Number(s) |
D02.033.800.609 D09.853.609
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Mannitol".
Below are MeSH descriptors whose meaning is more specific than "Mannitol".
This graph shows the total number of publications written about "Mannitol" by people in this website by year, and whether "Mannitol" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2002 | 0 | 1 | 1 |
2003 | 1 | 0 | 1 |
2004 | 1 | 0 | 1 |
2006 | 0 | 1 | 1 |
2008 | 0 | 1 | 1 |
2011 | 0 | 1 | 1 |
2012 | 2 | 0 | 2 |
2018 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mannitol" by people in Profiles.
-
Godinho BMDC, Henninger N, Bouley J, Alterman JF, Haraszti RA, Gilbert JW, Sapp E, Coles AH, Biscans A, Nikan M, Echeverria D, DiFiglia M, Aronin N, Khvorova A. Transvascular Delivery of Hydrophobically Modified siRNAs: Gene Silencing in the Rat Brain upon Disruption of the Blood-Brain Barrier. Mol Ther. 2018 11 07; 26(11):2580-2591.
-
Huang S, Farrar CT, Dai G, Kwon SJ, Bogdanov AA, Rosen BR, Kim YR. Dynamic monitoring of blood-brain barrier integrity using water exchange index (WEI) during mannitol and CO2 challenges in mouse brain. NMR Biomed. 2013 Apr; 26(4):376-85.
-
Mc Causland FR, Prior LM, Heher E, Waikar SS. Preservation of blood pressure stability with hypertonic mannitol during hemodialysis initiation. Am J Nephrol. 2012; 36(2):168-74.
-
Dorfman JD, Burns JD, Green DM, DeFusco C, Agarwal S. Decompressive laparotomy for refractory intracranial hypertension after traumatic brain injury. Neurocrit Care. 2011 Dec; 15(3):516-8.
-
Fourcade J, Kudela P, Andrade Filho PA, Janjic B, Land SR, Sander C, Krieg A, Donnenberg A, Shen H, Kirkwood JM, Zarour HM. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J Immunother. 2008 Oct; 31(8):781-91.
-
Lu RP, Keilson G. Combination regimen of methylprednisolone, IV immunoglobulin, and plasmapheresis early in the treatment of acute disseminated encephalomyelitis. J Clin Apher. 2006 Dec; 21(4):260-5.
-
Jain A, Mohanka R, Orloff M, Abt P, Kashyap R, Cullen J, Lansing K, Bozorgzadeh A. University of Wisconsin versus histidine-tryptophan-ketoglutarate for tissue preservation in live-donor liver transplantation. Exp Clin Transplant. 2006 Jun; 4(1):451-7.
-
Josephson L. Management of increased intracranial pressure: a primer for the non-neuro critical care nurse. Dimens Crit Care Nurs. 2004 Sep-Oct; 23(5):194-207.
-
Kumar S, Jones TR, Oakley MS, Zheng H, Kuppusamy SP, Taye A, Krieg AM, Stowers AW, Kaslow DC, Hoffman SL. CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine. Infect Immun. 2004 Feb; 72(2):949-57.
-
Hirunpetcharat C, Wipasa J, Sakkhachornphop S, Nitkumhan T, Zheng YZ, Pichyangkul S, Krieg AM, Walsh DS, Heppner DG, Good MF. CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-based Montanides. Vaccine. 2003 Jun 20; 21(21-22):2923-32.